Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- context label "adults" assertion.
- association label "TCAs have also shown prophylactic benefit in cyclic vomiting syndrome, with a clinical response in over 75% of patients in controlled cohort studies." assertion.
- context label "adults" assertion.
- association label "Based on a randomized, double-blind trial,35 amitriptyline was recommended as a treatment option for interstitial cystitis or bladder pain, with the greatest symptom improvement in patients tolerating a daily dose of 50 mg" assertion.
- context label "adults" assertion.
- association label "TCAs have been used to treat chronic low back pain for decades and have been repeatedly shown to be more effective than placebo in reducing pain severity" assertion.
- DB00934 label "Maprotiline" assertion.
- DB00934 label "maprotiline" assertion.
- DB00934 label "maprotiline" assertion.
- context label "adults" assertion.
- association label "TCAs can serve as first-line or augmenting drugs for neuropathic pain, headache, migraine, gastrointestinal syndromes, fibromyalgia, pelvic pain, insomnia, and psychiatric conditions other than depression." assertion.
- DB00540 label "nortriptyline" assertion.
- DB00540 label "nortriptyline" assertion.
- DB00540 label "nortriptyline" assertion.
- DB00540 label "Nortriptyline" assertion.
- DB00540 label "Nortriptyline" assertion.
- DB00540 label "Nortriptyline" assertion.
- DB00540 label "Nortriptyline" assertion.
- DB00540 label "Nortriptyline" assertion.
- context label "adults" assertion.
- association label "Patients with irritable bowel syndrome have long been known to benefit from TCAs; the number needed to treat for symptomatic benefit over placebo is 3.5" assertion.
- context label "adults" assertion.
- association label "TCAs can serve as first-line or augmenting drugs for neuropathic pain, headache, migraine, gastrointestinal syndromes, fibromyalgia, pelvic pain, insomnia, and psychiatric conditions other than depression." assertion.
- context label "Children" assertion.
- association label "However, there are no sleep medications approved by the United States Food and Drug Administration and only one has been approved by the European Medicines Agency for pediatric insomnia; thus, most medications are prescribed off-label. Melatonin is widely used and safe in children with neurodevelopmental conditions. Gabapentin, clonidine, trazodone, and mirtazapine hold promise but require further study." assertion.
- DB00575 label "Clonidine" assertion.
- DB00575 label "Clonidine" assertion.
- DB00575 label "Clonidine" assertion.
- context label "Children" assertion.
- association label "However, there are no sleep medications approved by the United States Food and Drug Administration and only one has been approved by the European Medicines Agency for pediatric insomnia; thus, most medications are prescribed off-label. Melatonin is widely used and safe in children with neurodevelopmental conditions. Gabapentin, clonidine, trazodone, and mirtazapine hold promise but require further study." assertion.
- context label "Children" assertion.
- association label "However, there are no sleep medications approved by the United States Food and Drug Administration and only one has been approved by the European Medicines Agency for pediatric insomnia; thus, most medications are prescribed off-label. Melatonin is widely used and safe in children with neurodevelopmental conditions. Gabapentin, clonidine, trazodone, and mirtazapine hold promise but require further study." assertion.
- context label "Adults" assertion.
- association label "Doxepin, an H1 and H2 histamine receptor antagonist, has been administrated for over 30 years to treat and prevent chronic idiopathic urticaria (hives). Table 2 contains information on off-label use." assertion.
- DB01142 label "Doxepin" assertion.
- DB01142 label "Doxepin" assertion.
- DB01142 label "Doxepin" assertion.
- DB01142 label "Doxepin" assertion.
- DB01142 label "doxepin" assertion.
- context label "Adults" assertion.
- association label "nan" assertion.
- context label "Adults" assertion.
- association label "The observed efficacy of antidepressants as treatment for bulimia nervosa led to trials to evaluate their effect on binge eating disorder. Antidepressants that have shown promising results include bupropion, duloxetine, escitalopram, fluvoxamine, fluoxetine, imipramine, sertraline and venlafaxine" assertion.
- context label "Adults" assertion.
- association label "SSRIs including paroxetine, fluoxetine and escitalopram have been found as effective treatment for patients with premature ejaculation (Arafa and Shamloul, 2007). Premature ejaculation is also treated with clomipramine and sertraline (Balon, 1996; McMahon, 1998), as well as with dapoxetine, a member of the SSRI family, which is however not used to treat depression (Andersson et al., 2006)" assertion.
- DB01242 label "Clomipramine" assertion.
- DB01242 label "Clomipramine" assertion.
- DB01242 label "Clomipramine" assertion.
- context label "Adults" assertion.
- association label "Although antidepressants are not the first-line prophylactic strategy for patients with migraine, several clinical trials have proven their effectiveness in the treatment of migraine and related headache disorders (Koch and Jurgens, 2009). Especially TCAs: amitriptyline (Couch and Hassanein, 1979; Jackson et al., 2010; Kalita et al., 2013) and nortriptyline (Holroyd et al., 2001; Jackson et al., 2010) have the best evidence for use in migraine prevention. When amitriptyline is not tolerated by patients, treatment is continued with nortriptyline (Burch, 2019)." assertion.
- context label "Adults" assertion.
- DB00334 label "Olanzapine" assertion.
- DB00334 label "Olanzapine" assertion.
- DB00334 label "Olanzapine" assertion.
- DB00334 label "Olanzapine" assertion.
- DB00334 label "Olanzapine" assertion.
- DB00334 label "Olanzapine" assertion.
- association label "The SGA olanzapine is considered the most appropriate, followed by quetiapine and aripiprazole. Although off-label prescription of SGAs represents a common clinical practice in accordance with a worldwide trend, the use of long-acting injection formulations was considered inappropriate by 69% of psychiatrists in our sample. Attitudes on off-label use of Olanzapine in the treatment of BPD: Highly inappropriate = 26 (12.9%); Innapropriate = 26 (12.9%); Doubt = 86 (42.5%); Appropriate = 64 (31.7%); Highly appropriate = 0 (0%)" assertion.
- context label "Adults" assertion.
- association label "The SGA olanzapine is considered the most appropriate, followed by quetiapine and aripiprazole. Although off-label prescription of SGAs represents a common clinical practice in accordance with a worldwide trend, the use of long-acting injection formulations was considered inappropriate by 69% of psychiatrists in our sample.Attitudes on off-label use of Quetiapine in the treatment of BPD: Highly inappropriate = 50 (24.8%); Innapropriate = 20 (9.9%); Doubt = 75 (37.1%); Appropriate = 52 (25.7%); Highly appropriate = 5 (2.5%)" assertion.
- context label "Adults" assertion.
- association label "The on‐label indication for Brintellix is depression; we identified the following off‐label indications: schizophrenia, episodic mood disorders, anxiety disorders, personality disorders, bipolar depression, post‐traumatic stress disorder, and chronic pain." assertion.
- DB09068 label "Vortioxetine" assertion.
- DB09068 label "Vortioxetine" assertion.
- DB09068 label "Vortioxetine" assertion.
- DB09068 label "Vortioxetine" assertion.
- DB09068 label "Vortioxetine" assertion.
- DB09068 label "Vortioxetine" assertion.
- DB09068 label "Vortioxetine" assertion.
- context label "Children and adolescents" assertion.
- association label "Although not approved for the treatment of ADHD, clonidine and atypical antipsychotics (AAPs) are commonly used off-label in ADHD, especially when stimulants fail." assertion.
- context label "Adults" assertion.
- association label "Emerging research assesses the utility of venlafaxine in the management of chronic neuropathic pain." assertion.
- context label "Adults" assertion.
- association label "Moreover, although the studies were uncontrolled, a significant body of literature has highlighted the potential benefit of clozapine in the treatment of acute mania, the depressive phase of BD, and in overall mood stabilization, with some evidence suggesting its use not only in treatment-resistant schizophrenia but also in treatment-refractory BD." assertion.
- context label "Adults" assertion.
- association label "When we asked about the long-term treatment of BD, after having excluded from the analyses the 3 SGAs with a European indication for maintenance BD treatment (aripiprazole, olanzapine, and quetiapine), asenapine was considered either “highly appropriate” or “appropriate” by 44.6% of the respondents, while other off-label SGAs (clozapine, paliperidone, risperidone, ziprasidone) were mostly considered inappro- priate for maintenance bipolar treatment" assertion.
- context label "Children and adolescents" assertion.
- association label "Fluoxetine and escitalopram are the only agents with Food and Drug Administration approval for pediatric depression, but off-label bupropion prescriptions are common." assertion.
- context label "Adults" assertion.
- association label "The off label antipsychotic treatments we considered were sulpiride, olanzapine, pimozide, quetiapine, risperidone, haloperidol, tiapride, chlorpromazine, and aripiprazole. We estimated the effect of antipsychotics as a group, and also estimated effects of certain individual antipsychotic chorea drugs (i.e. olanzapine, risperidone, and tiapride) commonly taken in our cohort." assertion.
- DB00391 label "Sulpiride" assertion.
- DB00391 label "Sulpiride" assertion.
- context label "Adults" assertion.
- association label "The off label antipsychotic treatments we considered were sulpiride, olanzapine, pimozide, quetiapine, risperidone, haloperidol, tiapride, chlorpromazine, and aripiprazole. We estimated the effect of antipsychotics as a group, and also estimated effects of certain individual antipsychotic chorea drugs (i.e. olanzapine, risperidone, and tiapride) commonly taken in our cohort." assertion.
- DB00502 label "Haloperidol" assertion.
- context label "Children and adolescents (mean age 15.3 years)" assertion.
- association label "Stigler et al. [10] evaluated the effectiveness and tolerability of paliperidone for irritability in ASD. In this 8-week, prospective, open-label study, 21 (84%) of 25 subjects with ASD (mean age, 15.3 years) were considered responders to paliperidone (mean dosage, 7.1 mg/day), based on Clinical Global Impression (CGI)- Improvement and Aberrant Behaviour Checklist-Irritability sub- scale.v" assertion.
- DB01267 label "Paliperidone" assertion.
- DB01267 label "Paliperidone" assertion.
- DB01267 label "Paliperidone" assertion.
- DB01267 label "Paliperidone" assertion.
- DB01267 label "Paliperidone" assertion.
- DB01267 label "Paliperidone" assertion.
- DB01267 label "Paliperidone" assertion.
- DB01267 label "Paliperidone" assertion.
- DB01267 label "Paliperidone" assertion.
- context label "Children and adolescents" assertion.
- association label "Yamamuro et al. [13] have reported on 3 CAP cases with TS treated with paliperidone. In 2 cases, TS symptoms were remark- ably improved by switching from haloperidol to paliperidone ex- tended release, and in another case, paliperidone-extended release showed significant efficacy in treating TS symptoms as the first-line drug." assertion.
- context label "Adolescents (15-17)" assertion.